VMI
VHCP Management III Portfolio holdings
AUM
$504M
This Quarter Return
+364.08%
1 Year Return
+678.37%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$504M
AUM Growth
+$504M
(+211%)
Cap. Flow
+$208M
Cap. Flow
% of AUM
41.31%
Top 10 Holdings %
Top 10 Hldgs %
90.41%
Holding
26
New
9
Increased
2
Reduced
5
Closed
8
Top Buys
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$115M |
| 2 |
Relmada Therapeutics
RLMD
|
$30M |
| 3 |
89bio
ETNB
|
$25.2M |
| 4 |
FTSV
Forty Seven, Inc. Common Stock
FTSV
|
$20.3M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$19.7M |
Top Sells
| 1 |
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
|
$15.9M |
| 2 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
$11M |
| 3 |
BioCryst Pharmaceuticals
BCRX
|
$7.76M |
| 4 |
Protagonist Therapeutics
PTGX
|
$7M |
| 5 |
Axsome Therapeutics
AXSM
|
$6.55M |
Sector Composition
| 1 | Healthcare | 97.82% |